Fujifilm is first to market with ultra high frequency ultrasound system with unprecedented image resolution capabilities
FUJIFILM VisualSonics, a world leader in ultra high frequency ultrasound imaging systems and subsidiary of FUJIFILM SonoSite, Inc., announces CE mark for the Vevo® MD, the world’s first Ultra High Frequency (UHF) clinical ultrasound system. With multiple successes in preclinical research over the last decade, today marks a major milestone for FUJIFILM VisualSonics as it expands into the clinical market.
“As the undisputed leader in ultra high frequency imaging systems, FUJIFILM VisualSonics once again advances the field of ultrasound with the launch of the Vevo MD,” said Masayuki Higuchi, president & CEO, FUJIFILM SonoSite, Inc. “We are proud to be the first to bring to market this exciting innovation that is sure to have high impact on the medical imaging community while expanding the product portfolio of FUJIFILM SonoSite.”
The Vevo MD is truly a unique ultrasound system, as it operates at much higher frequencies than any conventional ultrasound system currently available. Along with the Vevo MD system, FUJIFILM VisualSonics also introduces the UHF Series of transducers. This patented transducer technology is capable of operating in a range of frequencies up to 70 MHz, a tremendous increase in resolution compared to conventional ultrasound systems.
“The Vevo MD allows medical professionals to see what they have never seen before—unparalleled image resolution down to 30 micrometers. This is less than half the size of a grain of sand,” said Renaud Maloberti, vice president & general manager of FUJIFILM VisualSonics. “Imagine the great potential this technology has across unexplored applications to visualize the smallest, highly detailed anatomy in a way that has never been done before.”
“We believe this technology has a role to play in a range of clinical application areas from neonatology, vascular, musculoskeletal, dermatology, or other small parts that are within the first 3 cm of the body,” said Andrew Needles, director of marketing at FUJIFILM VisualSonics. “We also know that there are new and interesting areas to be discovered. The Vevo MD gives us and our users the opportunity to make those discoveries together.”
The Vevo MD is now commercially available with CE mark in the majority of European Union countries. For more information and contact details please visit www.vevomd.com or contact FUJIFILM VisualSonics at www.visualsonics.com.
FUJFILM VisualSonics, Inc., is a global leader in real time, in vivo, ultra high frequency ultrasound and photoacoustic imaging systems. With headquarters in Toronto, Canada and offices around the world, FUJIFILM VisualSonics is represented globally across an integrated sales network. FUJIFILM VisualSonics is recognized worldwide for providing cutting edge imaging technologies for the advancement of preclinical research particularly in cardiovascular, oncology, neurobiology and developmental biology areas. With the expansion of the product portfolio to include a new clinical product, FUJIFILM VisualSonics now broadens their range of imaging technologies across both preclinical and clinical markets. FUJIFILM VisualSonics is a subsidiary of FUJIFILM SonoSite, Inc. and a part of FUJIFILM Holdings Corporation. For more information, please go to: www.visualsonics.com.
FUJIFILM SonoSite, Inc. is the innovator and world leader in bedside and point-of-care ultrasound, and an industry leader in ultra high-frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by 26 subsidiaries and a global distribution network in over 100 countries. SonoSite’s portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, go to: www.sonosite.com .
FUJIFILM Holdings Corporation Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. In the year ended March 31, 2015, the company had global revenues of $20.8 billion, at an exchange rate of 120 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com .